Objective: Overactive bladder syndrome is chronic disease with high prevalence rate (9-42%). This syndrome requires long term therapy, but the treatment persistence is after 3 months over all 26% with further decline in one-year period as low as 18.5%. Main reasons for stopping the treatment are low efficacy, ` the medication didn't work as expected' and side effects. How much satisfied are patients with mirabegron persisting on its treatment? To answer this question, we provided secondary analysis of multicentre follow-up study of patients on mirabegron. We compared subjective and objective parameters between patients continuing mirabegron treatment and those who discontinued the medication. Design: Secondary analysis multicentre prospective follow-up. Settings: Ob/Gyn department First Faculty of Medicine, Charles University and General University Hospital, Prague. Methods: It is secondary analysis of multicentre prospective study following patients with mirabegron 50 mg treatment. We have analysed objective data from micturition diary and subjective data using visual analogue scales (UB-VAS -urgency bother visual analogue scale, and TS-VAS -treatment satisfaction visual analogue scale) and compared data between the group of patients continuing mirabegron treatment and patients who stopped the medication during the study. Results: We included 206 patients (176 women, 30 men) with diagnosis of overactive bladder. Patients continuing the treatment (group n 1) had baseline UBVAS 70.1 vs. 75.0 (p = n. s.) in patients who stopped the medication during the follow-up period (group n 2). Baseline episodes of severe urgency and urge incontinence where n 1 -5.1 vs. n 2 -6.2 (p = n. s.). Six months' urgency bother score UB-VAS was n 1 -32.4 vs. n 2 -58.9 (p < 0,001). Treatment satisfaction TSVAS was n 1 -80.3 vs. n 2 -57.7 (p < 0,001). Number of severe urgencies with or without urge incontinence was after 6 months n 1 -2.1 vs. n 2 -3.3 (p = n. s.), lower in group continuing the treatment. When comparing the data between patients stopping the medication for reason of low efficacy (group s 1) with patients stopping for other reasons (group s 2) UB-VAS bas: s 1 -68.5 vs. s 2 -43.9 (p = 0.001); TS VAS s 1 -45.1 vs. s 2 -58.4 (p = n. s.) and number of severe urgency with or without incontinence s 1 -5.9 vs. s 2 -3.2 (p = 0.009). Conclusion: Our data shows that patients expectation on treatment with mirabegron is not low. Patients accept treatment either without side effects or with decrease of severe urgency with or without urge incontinence around 50%. Regardless the reason the patients continuing the treatment scale treatment satisfaction -TSVAS over 70 points.